Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment

Addiction

Volumn 104, Issue 7, 2009, Pages 1193-1200

  Bell, James ^a,b,c,d   Trinh, Lieu ^e   Butler, Bethany ^f   Randall, Deborah ^c   Rubin, George ^b,e  

^a Langton Centre   (Australia)

^b South East Sydney and Illawarra Health Services   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e SYDNEY SOUTH WEST AREA HEALTH SERVICE   (Australia)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Buprenorphine; Heroin; Methadone; Mortality; Overdose; Retention

Indexed keywords

BUPRENORPHINE; METHADONE;

ADULT; ARTICLE; CAUSE OF DEATH; DRUG DETOXIFICATION; DRUG OVERDOSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METHADONE TREATMENT; MORTALITY; OPIATE ADDICTION; RISK; STATISTICAL ANALYSIS; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BUPRENORPHINE; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; METHADONE; MIDDLE AGED; NARCOTIC ANTAGONISTS; NEW SOUTH WALES; OPIOID-RELATED DISORDERS; POISSON DISTRIBUTION; REMISSION INDUCTION; RISK FACTORS; TIME FACTORS; YOUNG ADULT;

EID: 66749160901     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2009.02627.x     Document Type: Article

References (24)

1. Hulse G., English D. R., Milne E., Holman C. D. J. The quantification of mortality resulting from the regular use of illicit opioids. Addiction 1999 94 : 221 9.
2. Connock M., Juarez-Garcia A., Jowett S., Frew E., Liu Z., Taylor R. J. et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess 2007 11 : 1 171.
3. Clausen T., Anchesen K., Wall H. Mortality prior to, during and after maintenance treatment: a national, prospective cross-registry study. Drug Alcohol Depend 2008 94 : 151 7.
4. Davoli M., Bargagli A. M., Preuccil C. A., Schifano P., Belleudi V., Hickman M. et al. Risk of fatal overdose during and after specialist drug treatment: the VEdeTTE study, a national multi-site prospective cohort study. Addiction 2007 102 : 1954 9.
5. Buster M. C., van Brussel G. H. van den Brink W. An increase in overdose mortality during the first 2 weeks after entering or re-entering methadone treatment in Amsterdam. Addiction 2002 97 : 993 1001. (Pubitemid 34888487)
6. Umbricht A., Huestis M. A., Cone E. J., Preston K. L. Effects of high-dose intravenous buprenorphine in experienced opioid abusers. J Clin Psychopharmacol 2004 24 : 479 87.
7. Auriacombe M., Franques P., Tignol J. Deaths attributable to buprenorphine versus methadone in France [Letter]. JAMA 2001 285 : 45. (Pubitemid 32042714)
8. Luty J., O'Gara C., Sessay M. Is methadone too dangerous for opiate addiction? BMJ 2005 331 : 1352 3.
9. Kakko J., Svanborg K. D., Kreek M. J., Heilig M. 1-year retention and social function after buprenorphine assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet 2003 361 : 662 8.
10. Gibson A., Degenhardt L., Mattick R. P., Ali R., White J., O'Brien S. Exposure to opioid maintenance treatment reduces long-term mortality. Addiction 2008 103 : 462 8.
11. Soyka M., Apelt S. M., Lieb M., Wittchen H.-U. One-year mortality rates of patients receiving methadone and buprenorphine maintenance therapy. A nationally representative cohort study in 2694 patients. J Clin Psychopharmacol 2006 26 : 657 60.
12. Mattick R. P., Kimber J., Breen C., Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2008, Issue 2, CD002207. DOI:10.1002/14651858.CD002207.pub3.
13. Gandhi D., Jaffe J., McNary S., Kavanagh G., Hayes M., Currens M. Short-term outcomes after brief ambulatory opioid detoxification with buprenorphine in young heroin users. Addiction 2003 98 : 453 62.
14. Zanis D. A., Woody G. E. One-year mortality rates following methadone treatment discharge. Drug Alcohol Depend 1998 52 : 257 60.
15. Digiusto E., Shakeshaft A., Ritter A., O'Brien S., Mattick R. P., NEPOD Research Group. Serious adverse events in the Australian national evaluation of pharmacotherapies for opioid dependence (NEPOD). Addiction 2004 4 : 450 60.
16. Ling W., Wesson D. R., Charuavastra C., Klett C. J. A controlled trial comparing buprenorphine and methadone maintenance on opioid dependence. Arch Gen Psychiatry 1996 53 : 401 7.
17. Fugelstad A., Stenbacka M., Liefman A., Nylander M., Thiblin I. Methadone maintenance treatment: the balance between life-saving treatment and fatal poisonings. Addiction 2007 102 : 406 12.
18. Sindicich N., Degenhardt L. NSW Drug Trends 2007. Findings from the Illicit Drug Reporting System. Sydney : National Drug and Alcohol Research Centre, University of New South Wales 2008.
19. Volavka J., Verebely K., Resnick R., Mule S. Methadone dose, plasma level, and cross-tolerance to heroin in man. J Nerv Ment Dis 1978 166 : 104 9.
20. Zador D. A., Sunjic, S. D. Methadone-related deaths and mortality rate during induction into methadone maintenance, New South Wales, 1996. Drug Alcohol Rev 2002 21 : 131 6.
21. Van Ameijden E. J. C., Langendam M. W., Coutinho R. A. Dose-effect relationship between overdose mortality and prescribed methadone dosage in low-threshold maintenance programs. Addict Behav 1999 24 : 559 63.
22. Strain E. C., Walsh S. L., Bigelow G. E. Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine. Psychopharmacology 2002 159 : 161 6.
23. Pirnay S., Borron S. W., Giudicelli C. P., Tourneau J., Baud F. J., Ricordel I. A critical review of the causes of death among post-mortem toxicological investigations: analysis of 34 buprenorphine-associated and 35 methadone-associated deaths. Addiction 2004 99 : 978 88.
24. Zador D., Sunjic S. Deaths in methadone maintenance treatment in New South Wales, Australia 1990-1995. Addiction 2000 95 : 77 84. (Pubitemid 30096754)